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abstract 
The safety of travelling in patients suffering from chronic 
lung conditions is a frequently encountered problem amongst 
healthcare professionals. The objective of this paper is to review 
currently available literature, with the aim of clarifying such issues 
for doctors dealing with such concerns. The article will describe 
the effect of altitude on healthy and diseased lungs, assessment 
tools to be utilised when assessing patients with suspected or 
diagnosed chronic lung conditions and international guideline 
recommendations for chronic lung conditions.
abbrEviatioNs
COPD - Chronic obstructive pulmonary disease
FEV1 - Forced	expiratory	volume	in	one	second	
CPAP - Continuous positive airway pressure 
CXR - Chest X-ray
SpO2 - Peripheral capillary oxygen saturation
PaO2 - Arterial partial pressure of oxygen
BTS - British Thoracic Society 
iNtroductioN
In recent years there has been a progressive rise in the number 
of people who travel by air.1 The ease of travel as well as the 
increasing availability of lower cost travel makes journeys 
accessible to older or less financially advantaged travellers.2 
In addition, advances in the monitoring of many chronic 
respiratory diseases as well as the availability of medications 
have improved quality in the lifestyle of such patients, allowing 
chronically ill patients to consider the possibility of air travel. It 
has become common for people with lung disease to request to 
travel and in turn seek advice from their medical practitioners 
about related issues. Surprisingly, reports of serious incidents 
concerning travellers with lung disease are relatively rare. Since 
respiratory	problems	are	estimated	to	make	up	about	11%	of	
in-flight emergencies it is reasonable to assume that the burden 
of risk surrounding the flight itself, and later disruption of the 
journey, is significant.3 
FiGht ENviroNmENt aNd altitudE EFFEcts
Commercial aircraft are pressurised to cabin altitudes of up to 
8000	feet	(2438m)	although	this	ceiling	may	be	exceeded	in	
emergencies. Pressurization of the aircraft cabin is achieved 
using exterior air that is compressed and mixed with filtered 
and	re-circulated	cabin	air.	Up	to	50%	of	the	cabin	air	is	not	
re-circulated and is expelled, to be replaced with exterior air, 
with 20–30 complete air exchanges occurring per hour.4 At that 
altitude, the partial pressure of oxygen falls to the equivalent of 
breathing	15.1%	oxygen	at	sea-level.
The rapid reduction in pressure associated with ascent is 
usually well tolerated by the healthy lung. At cabin altitude even 
normal people can occasionally desaturate but will generally 
compensate by increasing alveolar ventilation,3 such that people 
with healthy lungs remain asymptomatic throughout the flight. 
On the other hand, apart from the usual health risks of 
airline flight, the principal additional challenge for patients with 
chronic respiratory disease is exposure to hypobaric hypoxia. 
Patients suffering from chronic respiratory illness may have 
mild hypoxaemia, which may even go unrecognized at times. 
Altitude exposure may worsen hypoxaemia in pulmonary 
disease. Compensatory pulmonary mechanisms may be 
inadequate in patients with lung disease despite normal sea-level 
oxygen requirements. In addition, compensatory cardiovascular 
mechanisms may be less effective in some patients who are 
unable to increase cardiac output.4 Such patients may be 
vulnerable to the relatively minor pressure changes, causing 
an enlargement of a pre-existing pneumothorax or rupture of 
an emphysematous bulla or other spaces containing air.3 The 
physiological compensation for acute hypoxaemia is mild to 
moderate hyperventilation, limited by the fall in arterial carbon 
dioxide tension (PaCO2) together with a moderate tachycardia.2 
prE-FliGht assEssmENt 
If there is doubt about the patient’s fitness to fly and if there 
are co-morbidities affecting fitness, assessment is advised. In 
general, the patient’s respiratory condition should be stable and 
the patient must have recovered from any recent exacerbation 
before travel. It is recommended that those patients with the 
following conditions should be assessed with at least, a history 
and physical examination: 
•	 Previous	air	travel	intolerance	with	significant	respiratory	
symptoms (dyspnoea, chest pain, confusion or syncope)
•	 Severe	chronic	obstructive	pulmonary	disease	(COPD)	
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(forced expiratory 
volume in one second 
(FEV1)	<30%	predicted)	or	
asthma
•	 Bullous	lung	disease	
•	 Severe	(vital	capacity	<1	litre)	
restrictive disease (including chest wall 
and respiratory muscle disease), especially 
with hypoxaemia and/or hypercapnia 
•	 Cystic	fibrosis	
•	 Co-morbidity	with	conditions	worsened	by	hypoxaemia	
(cerebrovascular disease, cardiac disease or pulmonary 
hypertension)
•	 Pulmonary	tuberculosis	
•	 Within	six	weeks	of	hospital	discharge	for	acute	
respiratory illness
•	 Recent	pneumothorax
•	 Risk	of	or	previous	venous	thrombo-embolism
•	 Pre-existing	requirement	for	oxygen,	continuous	positive	
airway pressure (CPAP) or ventilator support.2
During such an assessment patients should have their 
condition optimised, where possible, thus decreasing the 
risk of complications and potentially reducing the severity of 
hypoxaemia.
prE-FliGht scrEENiNG
history, physical ExamiNatioN, aNd spiromEtry
As part of a pre-flight screening evaluation, a detailed history 
and physical examination should be performed. Any previous 
flying history should therefore be explored, as this may yield 
important information on the symptoms or complications that 
may have occurred during or after previous air travel. Physicians 
should also consider the flight duration, destination, as well as 
the control of the disease. 
In the absence of any contraindication, the American 
Thoracic Society recommends that spirometry should be 
performed on patients with a history of acute or chronic lung 
disease or with symptoms suggestive of lung disease. Pulse 
oximetry at rest should also be done, with arterial blood gas 
confirmation in addition to this, if hypercapnia is suspected.4
assEssiNG thE risk For hypoxaEmia
Undoubtedly, people with respiratory disease who use long term 
oxygen treatment will need to continue using oxygen during 
a flight.3 The doubt arises in patients who have borderline 
hypoxaemia at sea level, in which case these patients need to be 
assessed thoroughly.
A number of methods of assessment for hypoxaemia risk 
during air travel are available. These include: 
•	 Sea-level	measurement	of	SpO2 and PaO2 
•	 The	use	of	equations	to	predict	hypoxaemia	at	altitude	
•	 Hypoxic	challenge	testing,	performed	under	either	
normobaric or hypobaric conditions.
Measuring SpO2 at sea level to risk-stratify patients has 
become recognized as a less reliable predictor of in-flight 
SpO2 compared to other methods. In the 2002 British Thoracic 
Society (BTS) guidelines, an SpO2 of	92–95%	without	risk	
factors or SpO2 greater	than	95%	was	used	to	indicate	that	
no further testing was warranted.5	However,	in	one	study,	
23%	of	patients	having	an	SpO2 greater	than	96%,	tested	by	
hypoxic challenge testing, experienced significant hypoxaemia 
warranting in-flight oxygen supplementation.6 In another 
study of 100 COPD patients, stratified on the basis of 
SpO2 thresholds from the 2002 BTS algorithm, who underwent 
pulse oximetry and normobaric hypoxic challenge testing, the 
sensitivity and specificity for these SpO2 thresholds were only 
59%	and	72%,	respectively.7 Despite this method being readily 
available, cheap, and not laborious, this tool is not considered 
sufficiently robust to screen patients. 
Predictive equations have also been used to estimate the 
risk of hypoxaemia at high altitude; they incorporate sea-level 
measurements of PaO2 and	other	parameters	such	as	FEV1 or 
anticipated cabin altitude.8,9 Many of the equations consistently 
overestimated the need for supplemental oxygen, thus incurring 
unnecessary additional cost.4 The novel non-linear predictive 
models represent a low cost option for the prediction of 
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significant hypoxia during flight and perform better than 
SpO2 in identifying those patients who require more formal 
assessment with hypoxic challenge testing.10 
Hypoxic	challenge	testing,	though	costly	and	time-
consuming, is now the preferred method to assess risk of 
hypoxaemia at altitude.4 It uses a decreased (normobaric) 
fraction	of	inspired	oxygen	(FiO2) to simulate the hypoxic 
conditions at altitude.4 It is performed in a specialist lung 
function unit after referral to a respiratory specialist.2	However,	
it is not available locally, rendering it difficult to advise our local 
patients accordingly, even in a hospital setting. The hypoxic 
challenge test is not a ‘fitness to fly’ test but is used to determine 
whether a patient needs in-flight oxygen; most importantly, even 
with in-flight oxygen and/or ventilator support, safety cannot 
be guaranteed.2 In fact, in one particular study, in PaO2 hypoxic 
altitude simulation testing, no difference was identified between 
COPD patients with and without respiratory symptoms.11 
FEV1	is	also	a	useful	marker	of	clinical	severity.	However,	
neither	resting	sea-level	oxygen	saturations	nor	FEV1 appear to 
predict hypoxaemia or complications accurately during or after 
air travel in patients with respiratory disease.2 
Based on the current literature, it can be concluded that air 
travel is	safe	for	most	patients.	However,	those	at	risk	of	hypoxia	
can benefit from supplemental in-flight oxygen.12 
Further	research	is	required	to	determine	whether	a	
symptom-based approach, for instance the Medical Research 
Council dyspnoea scale or clinical exercise testing might be 
more reliable for screening.2
coNtraiNdicatioNs to commErcial air travEl 
Certain patients suffering from pulmonary disease should 
be advised to avoid flying, either because of high risk of 
deterioration of their pre-existing condition or else, because they 
pose a risk to others. These include:
•	 Ongoing	pneumothorax	with	persistent	air	leak
•	 Major	haemoptysis
•	 Infectious	tuberculosis
•	 Usual	oxygen	requirement	at	sea	level	at	a	ﬂow-rate	
exceeding 4L/min.2,4
chroNic luNG disEasEs
obstructivE pulmoNary disEasE (asthma aNd copd) 
Before travel, patients should have their condition optimised, 
with the least possible symptoms as well as minimal use of 
reliever medication. They should carry their inhalers, including 
spacer, at all times. A patient should also be treated and has 
recovered from an exacerbation before being advised to 
travel. A bronchodilator given via a spacer is as effective as a 
nebuliser.	For	acute	exacerbations	on	board,	the	patient’s	own	
bronchodilator inhaler, ideally with a spacer, should be taken, 
and the dose repeated until symptomatic relief is obtained. 
According to BTS recommendations, it is advised that patients 
with	severe	or	brittle	asthma	or	severe	COPD	(FEV1<30%	
predicted) should consult their respiratory specialist beforehand 
for optimisation of their condition and the patient may consider 
carrying an emergency supply of prednisolone in addition 
to their usual medication.2 A recent study has suggested that 
hypoxic challenge testing should be performed for patients 
suffering from severe asthma.13
broNchiEctasis 
Positive sputum cultures should ideally be treated so as to 
optimize the patients’ condition. Bronchodilators should be 
prescribed as necessary. Nebulised antibiotics or nebulised 
bronchodilators are not generally required.2 
caNcEr 
Severe or symptomatic anaemia should be corrected 
beforehand, as should hyponatraemia, hypokalaemia and 
hypercalcaemia. Treatment (radiotherapy, chemotherapy and/
or stenting) for major airway obstruction, including upper 
airways stridor, should be complete before travel and sufficient 
time passed to enable the physician/oncologist to confirm 
stability. Patients with lymphangitis carcinomatosa or superior 
vena cava obstruction should only fly if essential, and must 
have in-flight oxygen available. Pleural effusions should be 
drained as much as possible before travel. Patients with major 
haemoptysis should not fly.2 
airborNE iNFEctioNs
Pre-flight assessment is advised for those with acute and 
chronic respiratory infections. Patients with infectious 
tuberculosis must not travel by public air transportation. 
World	Health	Organization	guidelines	state	that	‘physicians	
should inform all infectious and potentially infectious 
tuberculosis patients that they must not travel by air on any 
commercial flight of any duration until they are sputum smear-
negative on at least two occasions’.2
iNtErstitial luNG disEasE 
Patients should be carefully assessed. Supplemental oxygen 
should be considered if travelling at high altitude destinations. 
Carrying an emergency supply of antibiotics and prednisolone 
is recommended and medical advice on their usage should be 
given in the case of an exacerbation.2,4 
NEuromuscular disEasE aNd chEst wall disEasE 
International guidelines recommend that all patients with 
conditions causing severe extra-pulmonary restriction, 
including those needing home ventilation, should undergo 
hypoxic challenge testing before travel, if available. The decision 
to recommend in-flight oxygen and/or non-invasive ventilation 
must be made on an individual clinical basis. 2,4 
cystic luNG disEasE
In addition to hyperinflation within communicating airways, at 
an	altitude	of	8,000	feet,	Boyle’s	law	predicts	there	will	be	a	38%	
increase in the size of closed air-filled pockets within the body.14 
This gas expansion may be associated with an increased risk of 
pneumothorax in patients with bullous or cystic lung disease. 
In patients with chronic lung disease who are already at risk of 
hypoxaemia, the development of a pneumothorax in-flight could 
14 Volume 16, 2017  Issue 04
be a significant challenge. A previous history of pneumothorax 
may be more relevant in patients with lung disease, as rapid 
changes in barometric pressure may precipitate recurrence.4 
obstructivE slEEp apNoEa syNdromE
A doctor’s letter is required outlining the diagnosis and 
necessary equipment, and patients should keep their CPAP 
machine in the cabin. Alcohol and sedatives should be avoided 
before and during travel.2 
pNEumothorax 
Patients with a closed pneumothorax should not travel on 
commercial flights (with the exception of the very rare case of a 
loculated or chronic localised air collection which has been very 
carefully evaluated). Patients who have had a pneumothorax must 
have a chest X-ray (CXR) to confirm resolution before a flight, 
and flying is not advised for at least seven days after confirmation 
of	resolution.	For	patients	who	have	suffered	a	traumatic	
pneumothorax, the delay after full radiographic resolution 
should ideally be two weeks. Prognosis is good for those who 
opt for surgical intervention as a treatment measure. The risk of 
recurrence is higher in those with coexisting lung disease and 
does not fall significantly for at least one year. 2,4 Alternative forms 
of transport might be considered for other patients. 
thoracic surGEry 
In patients who underwent thoracic surgery with drain 
insertion, chest radiography is required after drain removal 
to ensure full expansion of the lung. Patients who have a 
pneumothorax after drain removal should not travel on 
commercial flights until full re-expansion has been confirmed 
on CXR. If chest radiography after drain removal confirms full 
re-expansion, it is prudent to wait for seven days before air 
travel. Any symptoms or signs suggesting the possibility of a 
pneumothorax should prompt a further CXR before air travel.2,4 
GENEral advicE 
Advance planning is of utmost importance. Our patients must 
be advised to seek medical attention before flying. Patients 
should be advised to carry around a list of their prescription 
medication, including oxygen, and to take an adequate supply 
to	last	the	whole	trip.	For	patients	who	make	use	of	portable	
oxygen concentrators, they must check in advance to see if 
the airline allows this and notify them accordingly. If needed, 
one should book extra services with the airline in advance, 
such as in-flight oxygen or wheelchairs, and check with the 
airline regarding the carriage of nebuliser machines, ventilators 
or CPAP machines. Travellers must also ensure that proper 
arrangements are made for travel insurance. The physician 
might also consider prescribing an emergency supply of 
antibiotics, with or without prednisolone, to be used as required 
by the patient, in case of an exacerbation whilst abroad.
additioNal coNsidEratioNs 
When evaluating patients for air travel, it is important to 
highlight the following points:
1. Even at 35,000 feet, different types of commercial aircraft 
can have widely differing cabin altitudes, ranging from an 
equivalent	of	approximately	5,400	feet	to	8,000	feet.15 In 
addition, commercial aircraft may also vary their cruising 
altitude a number of times during the flight, which in turn 
can alter cabin pressure.15,16
2. Respiratory symptoms may occur despite having a pre-
ﬂight	assessment.	One	study	found	18%	of	patients	with	
COPD developed respiratory symptoms despite having a 
pre-flight evaluation.17
3.	 Flight	duration	is	another	important	factor	to	consider.	
Longer flight durations are associated with increased 
symptoms,6 particularly when lasting over three hours.18
4. The levels of activity of the patient during the flight should 
also be considered. Patients with COPD, restrictive lung 
disease, and cystic fibrosis demonstrate significant worsening 
of hypoxaemia at simulated altitude with a workload 
equivalent to that of walking around the aircraft cabin.19-21
coNclusioN
Being diagnosed with a chronic lung condition does not 
mean that the patient can no longer travel but there are a 
number of limitations and implications. Patients must be 
advised to carefully plan their travel and to seek medical 
advice accordingly. 
International guidelines recommend that hypoxic challenge 
testing should be considered for patients with chronic lung 
diseases, since such patients are at risk of developing significant 
hypoxaemia and complications during air travel. In the absence 
of its availability locally, medical professionals must ensure that 
such patients have their respiratory status optimised, following 
a thorough assessment with the help of available tools, and that 
expert advice is sought when deemed necessary. 
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cardIac arrythmIas
mirEillE dEboNot
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arrythmias as any change from the normal sequence of 
electrical impulses. Cardiac arrythmias can be the result 
of either an abnormality of impulse formation [which can 
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else an abnormality in impulse conduction [which can lead 
to heart block].
During a normal cardiac cycle the electric impulse 
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through the atria where it reaches the atrio-ventricular node 
(AV node) and is then conducted through the ventricles.
When there is a change in the formation of the electrical 
impulse, impulses may be formed in the SA node at a very 
fast or slow rate (sinus tachycardia and sinus bradycardia, 
respectively). Sometimes the electrical impulses start to 
originate from areas in the heart outside the SA node. This 
may either occur occasionally (such as in supraventricular 
ectopic or ventricular ectopic) or else, all electrical impulses 
start to originate from outside the SA node (atrial fibrillation 
or ventricular fibrillation). The former type usually results in 
impulses which follow the baseline sinus rhythm but which are 
too fast or too slow. On the other hand, the latter usually result 
in electrical impulses which arise in a very fast and irregular 
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involves electrical impulses arising from the AV node at a very 
slow and regular rate, and supraventricular tachycardia, which 
involves electrical impulses arising from a site in the atria 
outside the SA node at a fast but regular rate.
When there is a change in electrical impulse 
conduction the result is heart block. 
Heart	block	can	be	classified	as	1st, 2nd or 3rd degree. In 
1st degree heart block there is a delay in the conduction 
of electrical impulse at the AV node. In 2nd degree heart 
block there is intermittent non-conduction of the electrical 
impulses at the AV node. In 3rd degree heart block none 
of the electrical impulses arising in the SA node are 
conducted through the AV node to the ventricles.
Cardiac arrythmias can usually be successfully managed 
with medication, discontinuing any causative drugs or else 
by inserting a pacemaker in the case of heart block. 
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